📊 AI Stock Rating — Summary

As of Q3 2025, XRAY's revenue stood at $904 million, with a notable net income loss of $427 million, translating to an EPS of -$2.14. The company generated $40 million in free cash flow, indicating some operational cash generation despite financial challenges. Revenue growth is currently facing obstacles, as reflected in the company's losses. Profitability is under pressure, with negative net margins and declining EPS. Nevertheless, XRAY maintained positive operating cash flow, supporting its ability to pay a consistent quarterly dividend of $0.16 per share. The balance sheet reflects a substantial net debt position of $2.117 billion, which could be a concern if net losses continue. Asset and liability management is crucial moving forward. Analysts set a price target range, suggesting up to $23, indicating potential upside from the current valuation context. Shareholder returns are primarily supported by regular dividends, but lack of share appreciation limits further growth prospects in total return.

AI Score Breakdown

Revenue Growth — Score: 3/10

Revenue was $904 million, but the company is experiencing growth challenges, as reflected in its negative earnings and absence of FCF information suggesting limited growth momentum.

Profitability — Score: 2/10

Operating margins are negative due to substantial net losses, with EPS at -$2.14. The financial efficiency is under considerable pressure.

Cash Flow Quality — Score: 5/10

The company generated $40 million in free cash flow, maintaining dividends while capital expenditures were manageable. However, overall liquidity should be monitored.

Leverage & Balance Sheet — Score: 4/10

With a net debt of $2.117 billion, XRAY's financial resilience is questionable unless profitability improves. Equity stands at $1.478 billion, but liabilities are substantial.

Shareholder Returns — Score: 3/10

XRAY offers consistent dividends but lacks notable price appreciation. No buybacks or significant price gains observed, potentially limiting total shareholder value.

Analyst Sentiment & Valuation — Score: 5/10

Analyst targets suggest potential upside, with a consensus target of $16 pointing to a possibly undervalued position. However, loss-making status affects perceived fair value.

⚠ AI-generated — informational only, not financial advice.